Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 75.8% in June

Mainz Biomed NV (NASDAQ:QUCY) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,367,490 shares, an increase of 75.8% from the June 15th total of 1,915,904 shares. Based on an average trading volume of 8,070,542 shares, the days-to-cover ratio is currently 0.4 days. Approximately 23.7% of the company’s stock are sold short.

Mainz Biomed Price Performance

Shares of NASDAQ:QUCY opened at $1.23 on Friday. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The firm has a market cap of $18.03 million, a price-to-earnings ratio of -0.03 and a beta of 2.28. The stock’s fifty day moving average is $1.98.

Analysts Set New Price Targets

QUCY has been the topic of several research analyst reports. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings raised Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mainz Biomed has a consensus rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.